Navigating Treatment Sequencing in HER2+ Metastatic Breast Cancer: Evidence-Based Approaches - Episode 1
Panelists discuss how a 52-year-old elementary school teacher diagnosed with HER2-positive (HER2+) breast cancer achieved pathologic complete response with neoadjuvant therapy but experienced metastasis 18 months after completing treatment, requiring first-line metastatic therapy.
Clinical Brief: Treatment Sequencing in HER2+ Metastatic Breast Cancer
Key Themes:
Key Points for Physicians:
Notable Insights:
Clinical Significance:
Treatment sequencing in HER2+ metastatic breast cancer requires careful assessment of disease characteristics, prior treatments, and timing of recurrence, with evidence supporting a shift to trastuzumab deruxtecan upon progression after first-line therapy.